How photoacoustic imaging works and why it matters clinically

Photoacoustic imaging (PAI) — also termed optoacoustic imaging — is a hybrid biomedical modality that combines pulsed optical excitation with ultrasound detection to deliver high-contrast, high-resolution images of tissue structure and function at clinically relevant depths. The underlying mechanism is the photoacoustic effect, first characterised by Alexander Graham Bell in the 1880s: absorbed pulsed light causes thermoelastic expansion in tissue, generating broadband acoustic waves that are detectable by standard ultrasound transducers.

The clinical significance of this physics is substantial. Because sound scatters far less than light in biological tissue, PAI achieves optical contrast — the ability to distinguish haemoglobin, melanin, lipids, and exogenous contrast agents — at ultrasonic imaging depths. This overcomes the fundamental limitation of purely optical techniques, which are confined to superficial tissue layers. The result is a modality that can image vascular anatomy, blood oxygenation (sO₂), and molecular targets without ionising radiation or contrast agent injection, according to WIPO-tracked patent filings and peer-reviewed literature spanning 2007 to 2024.

Three primary imaging architectures dominate the literature. Photoacoustic Computed Tomography (PACT) uses array-based detection with computational reconstruction, suited for deep-tissue and whole-organ imaging. Photoacoustic Microscopy (PAM) uses point-scanning in either optical-resolution (OR-PAM) or acoustic-resolution (AR-PAM) modes, optimised for high-resolution superficial imaging. Photoacoustic Endoscopy/Endomicroscopy (PAE/PAEM) uses miniaturised fiber-optic probes to deliver light internally for deep-organ access. Across all three, the dual PAT/US platform — combining photoacoustic tomography with conventional B-mode ultrasound — has emerged as the most clinically tractable configuration.

17 years of documented progress: the innovation timeline

The photoacoustic imaging innovation record in this dataset spans from 2007 to 2024 — approximately 17 years of documented progress — and falls into three distinct phases defined by the maturity of systems and the proximity to clinical deployment.

The Foundational Phase (2007–2013) established proof-of-concept imaging. A 2007 study from the University of California, Irvine demonstrated sub-200 µm resolution in phantoms using interferometric detection. A 2014 result from Karl-Franzens-University Graz achieved sub-100 µm 3D resolution using CCD-camera-based ultrasound detection. The landmark translational milestone of this era was a 2013 report from the Helmholtz Center Munich of a functional optoacoustic handheld video-rate 3D scanner demonstrated in human volunteers — the first demonstration that the technology could be used on living people outside a laboratory phantom setting.

The Development and Scale-Up Phase (2015–2019) saw systems expand to breast-specific tomography, MEMS-enhanced microscopy, LED-based sources, and clinical-grade handheld probes. FUJIFILM Corporation filed multiple active US design patents for probe designs between 2016 and 2017, marking a decisive move toward commercialisation. POSTECH introduced a programmable real-time clinical photoacoustic and ultrasound imaging system in 2016.

The Clinical Translation Phase (2020–2024) is characterised by cost reduction, LED-based sources, dual-modal PAT/US platforms, and regulatory-ready designs. Literature volume on LED sources and portable systems accelerated markedly post-2019, signalling commercialisation pressure. FUJIFILM’s 2024 EP-active patent focusing on monitoring blood vessel regeneration treatment represents a direct therapeutic monitoring application with regulatory and commercial implications.

“The literature volume on LED sources and portable photoacoustic systems accelerated markedly post-2019, signalling commercialisation pressure across the field.”

Four technology clusters driving photoacoustic imaging forward

Photoacoustic imaging research organises into four distinct technical clusters, each representing a different approach to the core challenge of delivering light, detecting sound, and reconstructing images at clinically useful speed and cost.

Cluster 1: Laser-based high-power pulsed systems

The traditional architecture employs Q-switched Nd:YAG or OPO lasers delivering nanosecond pulses at high peak energies. These systems achieve the deepest penetration depths and highest signal-to-noise ratios but are bulky and expensive. NIR-I excitation at 700–900 nm is established as optimal for depth, while NIR-II windows (1000–1700 nm) are being explored for further gains, as characterised by Nanyang Technological University in 2019 across wavelengths of 532 nm, 800 nm, and 1064 nm.

Cluster 2: LED and low-cost portable light sources

A major innovation thrust since approximately 2018 has been replacing expensive class-IV lasers with pulsed LED arrays. LED systems sacrifice peak power but gain portability, safety, and cost-effectiveness, enabling point-of-care and resource-limited settings. Signal averaging at high pulse repetition frequencies — up to 16 kHz — compensates for lower per-pulse energy. Research from Tongji University (2020), the University of California San Diego (2018), and Penn State Hershey College of Medicine (2021) has characterised LED system performance and validated the approach for human vascular imaging.

Cluster 3: Fiber-optic, all-optical, and minimally invasive systems

To access deep-seated or internal anatomy, fiber-optic light delivery and all-optical ultrasound detection — using interferometric sensors and optical resonators rather than piezoelectric elements — have been developed. These architectures enable miniaturised endoscopic probes, wearable configurations, and electromagnetic-interference-free imaging environments. King’s College London and the Royal Free Hospital have been central contributors to this cluster, demonstrating an all-optical dual photoacoustic and OCT intravascular probe in 2018. A 2022 advance from King’s College London integrated wavefront shaping with a PVDF/ITO transparent sensor on a multimode fiber, enabling optical-resolution forward-viewing endoscopy — a configuration essential for tumour biopsy guidance.

Cluster 4: MEMS-enhanced and high-speed scanning systems

Microelectromechanical systems (MEMS) scanners have dramatically increased PAM imaging speed, enabling video-rate acquisition and handheld miniaturised devices with both OR-PAM and AR-PAM capability. POSTECH has been the dominant contributor to this cluster, publishing on high-speed simultaneous multiscale photoacoustic microscopy in 2019. The California Institute of Technology contributed a novel architecture — photoacoustic topography through an ergodic relay (PATER) — for functional imaging and biometric applications in vivo in 2020.

Application domains: from breast oncology to industrial inspection

Photoacoustic imaging’s application landscape is broader than its medical imaging origins suggest. Six distinct domains are represented in the dataset, ranging from the most mature clinical applications to emerging industrial verticals.

Oncology and breast cancer screening

Breast imaging is the most mature clinical application in this dataset. PAI’s high vascular contrast maps tumour angiogenesis without ionising radiation or contrast injection. Multiple dedicated breast tomography systems have been reported, including hemispherical detector array configurations from the University of Twente (2013, 2019) and a real-time 3D photoacoustic visualisation system for human limbs from Japan Probe Co. (2018). The absence of ionising radiation positions PAI as a complement to mammography for dense-breast screening populations, as noted in FDA-relevant regulatory discussions in the literature.

Ophthalmology and retinal imaging

Photoacoustic ophthalmoscopy (PAOM) has demonstrated capability to image retinal vasculature, choroidal vessels, and retinal pigment epithelium (RPE), complementing OCT. Safety studies from the University of Michigan (2022) have confirmed viability within ANSI limits. The University of Michigan group has also reported photoacoustic imaging of intraocular tumours including retinoblastoma and uveal melanoma (2017).

Cardiovascular and vascular imaging

PAI enables label-free mapping of blood oxygenation (sO₂), vascular anatomy, and arterial plaque composition. Intravascular dual-modal probes combining photoacoustic and OCT imaging have been demonstrated in coronary artery disease contexts by researchers at the Royal Free Hospital and King’s College London (2018). A 2022 review from the Fifth People’s Hospital of Chengdu surveyed the current status of clinical photoacoustic/ultrasound dual-modal imaging, reflecting growing clinical adoption interest in China.

Surgical guidance and interventional imaging

PAI via fiber-optic probes enables intraoperative visualisation of blood vessels, nerves, and instrument tips hidden beneath tissue surfaces — targeting minimally invasive surgical workflows. Johns Hopkins University published a comprehensive review of photoacoustic imaging for surgical guidance in 2020. Washington University in St. Louis demonstrated optical-resolution photoacoustic endomicroscopy in vivo as early as 2015.

Inflammation, dermatology, and musculoskeletal imaging

Superficial applications exploit the high spatial resolution of PAM for imaging inflammatory disease — including rheumatoid arthritis and psoriasis — skin lesions, and musculoskeletal structures. The University of Cambridge Cancer Research UK group published on optoacoustic imaging in inflammation in 2021. The University of Michigan published on musculoskeletal and abdominal PAI applications in 2023, the most recent academic contribution in the dataset.

Non-destructive testing and industrial inspection

Beyond biomedicine, PAI has been applied to imaging railway cracks, lithium-metal battery defects, silicon wafer damage, porosity characterisation, and heritage artworks — an underexplored but growing vertical documented by Shanghai Jiao Tong University in 2021. According to IEEE publications in this space, the non-contact, depth-resolved inspection capability of PAI offers advantages over conventional ultrasonic testing in materials where coupling is problematic.

Patent geography and assignee concentration

FUJIFILM Corporation is the most prolific patent assignee in this dataset, holding 6 active utility and design patents filed in US and EP jurisdictions between 2016 and 2024. These patents cover probe designs — including fiber arrangement and transducer geometry — and image evaluation methods. This makes FUJIFILM the most active corporate IP holder in the photoacoustic imaging space within the retrieved dataset.

The US patent record includes 5 active FUJIFILM probe design patents filed between 2016 and 2017. The EP record includes 2 active FUJIFILM patents: a 2018 patent covering photoacoustic image generation methods and a 2024 patent focused on photoacoustic image evaluation for blood vessel regeneration monitoring. The 2024 EP filing is particularly significant as a direct therapeutic monitoring application with regulatory and commercial implications, as tracked by the European Patent Office.

On the academic side, POSTECH (South Korea) has made multiple high-impact contributions on MEMS-enhanced PAM, handheld systems, and programmable clinical platforms (2016–2019). The University of Michigan (USA) has led on ophthalmology, intraocular tumour imaging, and musculoskeletal PAI (2017–2023). King’s College London and University College London (UK) have led on minimally invasive PAI, all-optical probes, and fiber-optic sensors (2018–2022). The University of Twente (Netherlands) has focused on breast tomography and LED-based systems (2013–2020). Helmholtz Center Munich and Technical University of Munich (Germany) have led on volumetric MSOT and image reconstruction (2013–2022).

Innovation is broadly distributed across North America, Europe, East Asia, and Singapore/Australia, with no single geography dominating. However, corporate patent filing activity is concentrated in Japan (FUJIFILM) for hardware and probe design, while academic innovation is split between the US, UK, South Korea, and Germany. IP strategists entering the probe design space must conduct freedom-to-operate analysis around FUJIFILM’s portfolio, particularly around fiber arrangement, transducer geometry, and ergodic relay architectures — a point reinforced by patent databases maintained by the European Patent Office.

Emerging directions and strategic implications for 2026

The most recent records in this dataset (2022–2024) point to five emerging directions that will shape the photoacoustic imaging competitive landscape over the near term.

1. Blood vessel regeneration monitoring

FUJIFILM’s 2024 EP-active patent introduces quantitative tracking of blood vessel regeneration treatment over time using differential photoacoustic image analysis. This is a direct therapeutic monitoring application — moving PAI from diagnosis toward treatment response assessment — with significant regulatory and commercial implications for oncology and wound care markets.

2. Forward-viewing photoacoustic endomicroscopy with transparent sensors

A 2022 contribution from King’s College London integrates wavefront shaping with a PVDF/ITO transparent sensor on a multimode fiber, enabling optical-resolution forward-viewing endoscopy. This configuration is essential for tumour biopsy guidance — a high-value interventional application that has previously been inaccessible to photoacoustic methods.

3. Theranostic contrast agents and “turn-on” probes

Two 2022 publications — from Xi’an Jiaotong University and the University of Queensland — represent a convergence of molecular imaging and therapy, with stimuli-responsive nanomaterials and organic dyes providing target-specific photoacoustic signal activation. “Turn-on” activatable contrast agents offer exquisite disease specificity but face significant regulatory hurdles for in vivo human use. Partnerships between imaging hardware companies and pharmaceutical/nanomedicine developers will be necessary to realise this potential.

4. Extended depth-of-focus microscopy

A 2022 study from the Helmholtz Center Munich extended volumetric imaging depth-of-field 17-fold by coupling Bessel beam illumination with axicon acoustic detection. This addresses a fundamental limitation of OR-PAM for fast 3D imaging, and represents a hardware-level breakthrough that could accelerate clinical adoption of high-resolution photoacoustic microscopy.

“A 2022 Helmholtz Center Munich study extended photoacoustic volumetric imaging depth-of-field 17-fold — addressing a fundamental limitation of optical-resolution PAM for fast 3D imaging.”

5. Image quality standardisation for clinical approval

A 2022 systematic review from Aristotle University of Thessaloniki on image quality improvement techniques and assessment adequacy in clinical optoacoustic imaging reflects growing regulatory and standardisation activity. Standardisation is a prerequisite for FDA/CE clearance and will determine commercial timelines for the field. Product developers targeting FDA 510(k) pathways should position PAT as an add-on module to cleared ultrasound platforms — the most clinically tractable near-term path, given established ultrasound infrastructure and clinical familiarity. This approach aligns with guidance from bodies such as ISO on imaging system performance standards.